Yumanity Therapeutics

Recent executive movements at Yumanity Therapeutics

Ajay Verma has joined the company as Executive Vice President and Head of Research & Development  (news posted on April 14 2021).
Ellen Forest has joined the company as Chief Human Resources Officer  (news posted on August 25 2020).

Create an alert
to follow the executive moves at Yumanity Therapeutics.

Most searched biographies at Yumanity Therapeutics

• Richard Peters, Chief Executive Officer
• Tony Coles, Executive Chairman of the Board
• Daniel Tardiff, Interim Head of Research

Click on an executive to view his biography >

Latest M&A news in Biotechnology.

DiaSorin has announced the acquisition of Luminex (posted on Apr 16, 2021).
Bio-Techne has acquired Asuragen (posted on Apr 7, 2021).
EQT has announced the acquisition of Cerba Healthcare (posted on Apr 1, 2021).

Other contacts in the Biotechnology industry

• Tal Zaks - Non-Executive Director at Adaptimmune Therapeutics
• Sylke Hassel - Senior Vice President and Business leader, Global Head of Mammalian and Microbial Business at Lonza
• John Dunn - Director at Acer Therapeutics

Learn more about the Biotechnology industry >

Latest news about Yumanity Therapeutics

Yumanity Therapeutics on Wikipedia, Google News & Yahoo Finance

Yumanity Therapeutics on LinkedIn, Twitter & YouTube

Yumanity Therapeutics has 1,646 competitors including Biogen (United States (USA)), Eurofins (France) and Actelion (Switzerland).

Contact by email its executives including Richard Peters

Call Yumanity Therapeutics at +1 617....

View the org chart

Register to receive your alert

Report an error